Lifecarenews’ Post

Preliminary revenue figures for the 2023/24 financial year

Preliminary revenue figures for the 2023/24 financial year

We have just released our Q1 financial results. Find all the key figures and our full statement here: https://lnkd.in/dsWrDgdF #StevanatoGroup #FinancialResults #ManagingComplexityDeliveringValue

We have released our Q3 financial results. Read the highlights and our full statement here: https://lnkd.in/d4StwGpA.. #StevanatoGroup #Q3 #FinancialResults #ManagingComplexityDeliveringValue

Are the 2026 MFPs a good deal? That question is tougher to answer than you might think, and the factors to consider vary by stakeholder. My colleagues and I just published a new article in Milliman's series on IRA price negotiation with thoughts on the recently released MFPs. Check it out here: https://lnkd.in/eyRXHM8W #inflationreductionact #medicarepartd #milliman

❓ How are the 2026 MFPs going to impact different #medicareadvantage stakeholders? Check out my colleagues Katie Holcomb, Maddie Cline, Jake Klaisner, Jennifer Carioto, and Gabriela Dieguez's article discussing just that! The closing sentence of this article, to me, is telling for the industry: "Working toward a clear understanding of the financial implications these significant changes may bring should be a focal point for manufacturers, plan sponsors, PBMs, and pharmacies over the coming years."

Great info from fellow pricing and spend management wonks Jason Winmill and Ken Callander. The wide and unpredictable nature of rate increases is especially frustrating because of *when* it occurs - typically after corporate budgets are finalized. What do you do if you haven't proactively budgeted for or set rate expectations with your firms and you get hit with a surprise increase? Negotiate, sure, but you've lost the first mover advantage. Defensive measures like tightening invoice review controls and adding matter-level bidding are a good first response, but the bigger play is shifting the work in-house, to flex talent, or alternative service providers. Move the work that does not need an Am Law 50 attorney to mitigate the impact those rate increases have on your budget. And of course, start thinking about this earlier in 2025 before budgeting is complete, so you have a plan in place. Any other tips on how to handle these "scattershot" rate increases? https://lnkd.in/g5-BR-rA

Are you aware of the biggest bear trap of patient-facing pricing research? Read our white paper to explore this bear trap and how econometric modeling could save your pricing strategy: https://lnkd.in/eZF-bSAf Edited by Kim Robinson

Record revenue and double-digit growth: We look back on an extremely successful year 2023. We published the annual financial statements for the financial year 2023 today and they show a year-over-year increase in revenue of +17% to a record of € 1,498.4 million. Our EBITDA totalled € 780.5 million in the reporting period, an increase of +14% compared to 2022. Thus we are continuing our dynamic and profitable growth track over the last years in 2023 and significantly exceeding our targets we have set ourselves. 

ICER’s UPI reports do more harm than good: They have serious methodological limitations, contradict ICER’s core value assessment framework, and ignore a tremendous amount of evidence submitted by manufacturers.  One critical limitation is ICER’s failure to adjust for inflation when calculating the headline number in the report. If ICER simply followed this best practice for economic analysis and inflation-adjusted their findings using CPI-U, the estimated $815 million “increase” in this year’s report disappears, becoming instead a $10 million decrease, causing the premise of the entire report to collapse. Read more below: